22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
The U.S. Department of the Treasury’s Interim Rule establishing filing fees for joint voluntary not...
Read More >
Have you ever wondered when Massachusetts’ 6-year statute of repose for defective design, planning ...
Read More >
Financial Institutions M&A sector trends: Asset/wealth management — H1 2020 and outlook for H2 2020...
Read More >
In Hinterberger v. City of Indianapolis, the Seventh Circuit recently reminded litigants of their un...
Read More >
1. The National Labor Relations Board (NLRB) has adopted a new standard for determining whether cont...
Read More >
On October 22, 2019, the U.S. Department of Labor (DOL) announced proposed regulations that would al...
Read More >